As several biotechs focus on developing lucrative hepatitis C drugs, a Cambridge firm has received funding to help develop a hepatitis C vaccine.
VBI Vaccines (Nasdaq: VBIV) has secured $6.29 million from a variety of venture capital investors, including new investor RTW Investments, with participation from ARCH Venture Partners and Perceptive Advisors.
Under the terms, VBI sold 3 million shares of stock at approximately $2 a share, resulting in the raise.
Read more....Labels: HCV vaccine, therapeutic vaccine